Friday, July 1, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Novel fusion inhibitor blocks SARS-CoV-2 spike-mediated cell-cell fusion

by Medical Finance
in Coronavirus
Study: A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern. Image Credit: CKA/Shutterstock
9
SHARES
101
VIEWS
Share on FacebookShare on Twitter

In a recent study published in the journal Viruses, researchers constructed a novel fusion inhibitor−based recombinant protein, referred to as 5−Helix, to block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) mediated cell-cell fusion.

Study: A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern. Image Credit: CKA/Shutterstock
Study: A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern. Image Credit: CKA/Shutterstock

It found that 5−Helix potently inhibited infection by SARS−CoV−2 pseudoviruses (PsV) and its variants of concern (VOCs), including Omicron; additionally, it inhibited infection by authentic SARS−CoV−2 wild−type (wt) nCoV−SH01 strain and Delta VOC.

Background

Amid the continuous emergence of SARS-CoV-2 VOCs and variants of interest (VOIs, e.g., Lambda), there is an urgent need to develop effective, broader−spectrum antivirals against SARS−CoV−2, the causative agent of the deadly coronavirus disease 2019 (COVID-19).

To date, neutralizing antibody (NAb) therapeutics and vaccines against COVID-19 have primarily targeted the receptor-binding domain (RBD) and N-terminal domain (NTD) of the SARS-CoV-2 S1 subunit.

However, the researchers have now shifted focus to heptad repeat 1 (HR1) and heptad repeat 2 (HR2) domains of the S2 subunit as targets for viral fusion inhibitors. These domains in the S2 subunit are only transiently exposed immediately after binding between the RBD in S1 and the host cell receptor angiotensin-converting enzyme 2 (ACE2).

Due to space constraints during the fusion-intermediate state, HR1 and HR2 domains are not accessible to immunoglobulin G (IgG) molecules with a molecular weight of 150 kDa. Moreover, they are the most conserved regions of the S protein; consequently, researchers speculated that antivirals targeting these domains will have a higher genetic barrier to resistance.

Among the HR1 and HR2, HR2 is a better target for broad−spectrum viral fusion inhibitors since its amino acid sequences are more conserved than that of HR1. It is worth noting here that the amino acid sequences of HR1 and HR2 domains of SARS−CoV−2 are also 92.6% and 100% similar to those of HR1 and HR2 of SARS−CoV, respectively.

Since 5−Helix is a recombinant protein, it may also elicit antibodies after repeated use in COVID−19 patients. As opposed to anti−human immunodeficiency virus (HIV) therapeutics, which are used for prolonged periods, an antiviral agent against SARS−CoV−2 needs to be used for a few days only. Therefore, antibodies induced against 5−Helix might not hinder its future clinical application.

Previously, the authors had engineered several peptide−based fusion and entry inhibitors targeting the HR1 domain of several viruses, including HIV-1 and SARS-CoV-2.

About the study

In the present study, they engineered the fusion protein 5−Helix and assessed its inhibitory activity on SARS−CoV−2 S−mediated cell-cell fusion. They counted the percentage of fused cells under a fluorescence microscope to compute their half-maximal inhibitory concentration (IC50). They also observed the secondary structure of 5−Helix using circular dichroism (CD) spectroscopy.

They synthesized SARS-CoV-2 PsV and determined their tissue culture infectious dose (TCID50) using the Reed−Muench method. To examine the inhibitory activity of 5−Helix against SARS-CoV-2 PsV infection, they seeded Caco−2 cells in a 96−well plate, added 100 TCID50 of SARS-CoV-2 PsV, mixed with an equal volume of 5−Helix, which was serially diluted with phosphate buffer saline (PBS) at 37 °C for 30 minutes.

The mixture was transferred to the Caco−2 cells, rinsed with a fresh medium after 12 hours, and finally, they measured the luminescence after 48 hours of incubation. A luminescence value ten−fold higher than the control indicated a positive result.

They also performed inhibitory activity assessments of 5−Helix against authentic SARS-CoV-2 infections in a Biosafety Level 3 (BSL−3) laboratory. To this end, they seeded Calu−3 cells into a 96−well plate, added authentic SARS−CoV−2 at 0.01 multiplicity of infection (MOI) mixed with an equal volume of 5−Helix, serially diluted with PBS maintained at 37°C for 30 minutes. The mixture was transferred to the Calu−3 cells, and 48 hours later, they collected the supernatants and quantified SARS−CoV−2 nucleocapsid (N) gene copies using quantitative reverse−transcription polymerase chain reaction (RT−qPCR).

They used the cell counting kit−8 to measure the 5−Helix cytotoxicity to Huh 7 cells, Caco−2 cells, and Calu−3 cells. Lastly, they used the biolayer interferometry (BLI) instrument Octet QK system to record 1:1 real−time binding between 5−Helix and biotinylated SARS−CoV−2 HR2P and compute the equilibrium dissociation constant (KD).

Study findings

5−Helix fusion protein consisted of three copies of HR1P and two copies of HR2P and formed 5−helix−bundle (5−HB) that exposed one hydrophobic groove that could be accessed and bound by the HR2 region in the S2 subunit of the SARS−CoV−2 S protein. The purified 5−Helix protein showed a single band of about 24 kDa in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),  similar to its theoretical molecular weight.

As observed during CD spectroscopic examination, it displayed a helical structure with a high α−helicity of almost 100%, and a melting temperature (Tm) of 52 °C, indicating its thermo-stability.

Enzyme-linked immunosorbent assay (ELISA) showed that 5-Helix could bind with SARS−CoV−2 HR2P peptide with high affinity and a KD of 17.3 nM suggested that this binding was specific and strong. Additionally, it could block six-helix bundle (6−HB) formation between the HR1 and HR2 peptides of SARS−CoV−2.

5−Helix effectively inhibited SARS−CoV−2 PsV infection in Caco−2 cells with a mean IC50 value of 243 nM. It inhibited SARS−CoV−2 S−mediated cell-cell fusion, and pseudotyped SARS−CoV−2 wt strain D614G and five VOCs, including Alpha, Beta, Gamma, Delta, and VOI Lambda with IC50 of 364, 170, 142, 369, and 238 nM, respectively. Unexpectedly, 5−Helix displayed the highest inhibitory activity against Omicron PsV infection with IC50 of 141 nM.

Similar to the HR1P peptide, 5−Helix at 30 μM concentration showed no significant cytotoxicity and had a selectivity index (SI) over 80, indicating that it was not cytotoxic in vitro. It was also potent against the authentic SARS−CoV−2 wt strain, nCoV−SH01, and the Delta VOC.

Conclusions

The study findings confirmed that 5−Helix had a lower production cost and longer half−life than a pan−CoV fusion inhibitor EK1. Moreover, it exhibited about two− to three−fold higher antiviral activity against SARS−CoV−2 and its VOCs than EK1. Furthermore, since 5−Helix targeted the more conserved HR2 domain, it had a higher genetic barrier to resistance than the EK1 peptide and lipopeptides. More importantly, it was possible to synthesize 5−Helix on a large scale in yeast or Escherichia coli expression systems.

Taken together, these findings suggest that the 5−Helix fusion protein is a potent inhibitor of all currently circulating and emerging SARS−CoV−2 variants thus, an ideal candidate for development as a COVID-19 prophylactic or therapeutic agent.    

Journal reference:

  • Xing, L.; Xu, X.; Xu, W.; Liu, Z.; Shen, X.; Zhou, J.; Xu, L.; Pu, J.; Yang, C.; Huang, Y.; Lu, L.; Jiang, S.; Liu, S. (2022). A Five−Helix−Based SARS−CoV−2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS−CoV−2 and Its Variants of Concern. Viruses. doi: https://doi.org/10.3390/v14030597 https://www.mdpi.com/1999-4915/14/3/597
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. Image Credit: Kateryna Kon/Shutterstock

Memory B cell repertoire in a longitudinal cohort of individuals receiving 3 COVID-19 mRNA vaccine doses

by Medical Finance
June 30, 2022
0

In a recent study posted to the bioRxiv* preprint server, a team of researchers examined the memory B cell repertoire...

Study: P681 mutations within the polybasic motif of spike dictate fusogenicity and syncytia formation of SARS CoV-2 variants. Image Credit: Lightspring/Shutterstock

P681 mutations in SARS-CoV-2 spike protein determine fusogenicity

by Medical Finance
June 30, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers evaluated the importance of the P681 residue within the...

Surveying communities may be a useful tool for predicting COVID-19 case trajectories

5 things you should know about ‘free’ at-home covid tests

by Medical Finance
June 30, 2022
0

Americans keep hearing that it is important to test frequently for covid-19 at home. But just try to find an...

Study: COVID-19 onset reduced the sex ratio at birth in South Africa. Image Credit: Paulo Vilela/Shutterstock

Reduction in the sex ratio at birth found following the COVID-19 pandemic

by Medical Finance
June 30, 2022
0

The sex ratio at birth (SRB) has been defined as male/(male+female) live births. SRB, at the population level in South...

Omicron variant found to be much less sensitive to neutralizing antibodies than Delta

Scientists reveal how COVID-19 impacts the immune system’s ability to recognize other coronaviruses

by Medical Finance
June 30, 2022
0

Getting sick with a common cold doesn't make you immune to COVID-19, but a COVID-19 infection might, at least temporarily,...

Small cluster of neurons in the brain stem found to coordinate vocalization with breathing

Buffy Wicks turns her health history into legislation

by Medical Finance
June 30, 2022
0

In her short tenure as an elected official, California Assembly member Buffy Wicks hasn't been shy about sharing her most...

Next Post
Study: Hidden codes in mRNA: Control of gene expression by m6A. Image Credit: nobeastsofierce/Shutterstock

Gene expression regulation by N6-methyladenosine

Study: Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis. Image Credit: Exahardiwito / Shutterstock.com

COVID booster vaccination more effective relative to 2-dose series

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • 174318220 620x480
    High-throughput screening assay could identify new prostate cancer drugs
  • CRISPR locus on DNA sequence Catalin Rusnac 51742dddb09c41d2924841b1b4decc7a 620x480
    ‘Genetic scissors’ can give rise to unforeseen heritable mutations
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply